Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Larry S. who wrote (22960)	4/6/2000 3:41:00 PM
From: Hank	Respond to of 53068

Fair enough. Here are some facts for you to consider: 1. GUMM has only earned money in ONE quarter during it's entire history. 2. GUMM has never been able to publish ANY of the clinical studies it says supports it's claims regarding Zicam or Zicam Allergy Relief. 3. Although the FDA requires companies like GUMM to back it's product claims with clinical research, the FDA has NEVER reviewed the data from GUMM's clinical studies on Zicam to verify that these claims regarding Zicam's efficacy are legitimate (see the SEC 424 filing from 3/13/00). 4. Although GUMM claims to have struck an agreement with Swedish Match to develop nicotine gum, they have not finalized this agreement yet nor have they announced a roll out date for this product. 5. In spite of overly optimistic press releases by GUMM during 1999 claiming that Zicam sales were exceeding expectations, their recent press release implies that sales were actually below par. This is hardly a trait of trustworthy management.